{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SGLT2+inhibitor%2C+GLP-1+RA",
    "query": {
      "intervention": "SGLT2 inhibitor, GLP-1 RA"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T23:57:40.466Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05220917",
      "title": "Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cardiovascular Events",
        "Type2 Diabetes",
        "Renal Disease"
      ],
      "interventions": [
        {
          "name": "SGLT2 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "DPP-4 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "GLP-1RA",
          "type": "DRUG"
        },
        {
          "name": "2nd generation SU",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 781430,
      "start_date": "2021-08-01",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-09-30T23:57:40.466Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05220917"
    },
    {
      "nct_id": "NCT06593314",
      "title": "Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Heart Failure",
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "Message with EchoGo",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Standard Message",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 800,
      "start_date": "2025-08-06",
      "completion_date": "2026-10-15",
      "has_results": false,
      "last_update_posted_date": "2026-05-07",
      "last_synced_at": "2026-09-30T23:57:40.466Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06593314"
    },
    {
      "nct_id": "NCT02846233",
      "title": "Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "GLP1 receptor agonist",
          "type": "DRUG"
        },
        {
          "name": "basal insulin",
          "type": "DRUG"
        },
        {
          "name": "SGLT2 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2016-08",
      "completion_date": "2018-12",
      "has_results": true,
      "last_update_posted_date": "2020-11-10",
      "last_synced_at": "2026-09-30T23:57:40.466Z",
      "location_count": 1,
      "location_summary": "Fresno, California",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02846233"
    },
    {
      "nct_id": "NCT07444203",
      "title": "Transformative Research in Diabetic Nephropathy 2.0",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetic Nephropathies",
        "Kidney Diseases",
        "Renal Insufficiency, Chronic",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Sodium-glucose cotransporter 2 inhibitors (SGLT2i)",
          "type": "DRUG"
        },
        {
          "name": "Renin-angiotensin-aldosterone system blockade",
          "type": "DRUG"
        },
        {
          "name": "Glucagon-like peptide-1 receptor agonists (GLP 1 RA)",
          "type": "DRUG"
        },
        {
          "name": "Mineralocorticoid Receptor Antagonists(MRAs)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2025-11-12",
      "completion_date": "2028-11-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-09-30T23:57:40.466Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07444203"
    },
    {
      "nct_id": "NCT05390892",
      "title": "PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type2Diabetes",
        "ASCVD"
      ],
      "interventions": [
        {
          "name": "SGLT2 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "GLP-1 receptor agonist",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 6000,
      "start_date": "2022-09-26",
      "completion_date": "2029-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-09-30T23:57:40.466Z",
      "location_count": 36,
      "location_summary": "Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 31 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05390892"
    },
    {
      "nct_id": "NCT05040087",
      "title": "Changing the Natural History of Type 2 Diabetes (\"CHANGE\" Study)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Intensification of diabetes medication based largely on HbA1c levels",
          "type": "OTHER"
        },
        {
          "name": "Intensification of diabetes medication based on glucose levels",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Foundation for Atlanta Veterans Education and Research, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 127,
      "start_date": "2021-09-01",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-09-30T23:57:40.466Z",
      "location_count": 1,
      "location_summary": "Decatur, Georgia",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05040087"
    },
    {
      "nct_id": "NCT02787551",
      "title": "Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Insulin glargine/lixisenatide fixed ratio combination",
          "type": "DRUG"
        },
        {
          "name": "liraglutide",
          "type": "DRUG"
        },
        {
          "name": "exenatide",
          "type": "DRUG"
        },
        {
          "name": "exenatide extended-release",
          "type": "DRUG"
        },
        {
          "name": "albiglutide",
          "type": "DRUG"
        },
        {
          "name": "dulaglutide",
          "type": "DRUG"
        },
        {
          "name": "Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 514,
      "start_date": "2016-07-06",
      "completion_date": "2018-11-17",
      "has_results": true,
      "last_update_posted_date": "2022-03-25",
      "last_synced_at": "2026-09-30T23:57:40.466Z",
      "location_count": 74,
      "location_summary": "Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fountain Hills",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02787551"
    },
    {
      "nct_id": "NCT05526157",
      "title": "An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Kidney Disease",
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Finerenone (Kerendia, BAY 948862)",
          "type": "DRUG"
        },
        {
          "name": "Sodium-glucose cotransporter 2 inhibitors (SGLT2i)",
          "type": "DRUG"
        },
        {
          "name": "Glucagon-like peptide-1 receptor agonists (GLP 1 RA)",
          "type": "DRUG"
        },
        {
          "name": "Steroidal mineral corticoid receptor antagonists (sMRA)",
          "type": "DRUG"
        },
        {
          "name": "Non-steroidal mineral corticoid receptor antagonists (nsMRA)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50000,
      "start_date": "2022-10-01",
      "completion_date": "2024-09-05",
      "has_results": false,
      "last_update_posted_date": "2024-10-15",
      "last_synced_at": "2026-09-30T23:57:40.466Z",
      "location_count": 1,
      "location_summary": "Eden Prairie, Minnesota",
      "locations": [
        {
          "city": "Eden Prairie",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05526157"
    },
    {
      "nct_id": "NCT06046560",
      "title": "Diabetes Remote Intervention to improVe Use of Evidence-based Medications",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cardiovascular Diseases",
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "SGLT2 inhibitor, GLP-1 RA",
          "type": "DRUG"
        },
        {
          "name": "Education-First",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "27 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "27 Years to 79 Years"
      },
      "enrollment_count": 200,
      "start_date": "2021-03-22",
      "completion_date": "2023-07-25",
      "has_results": true,
      "last_update_posted_date": "2024-10-23",
      "last_synced_at": "2026-09-30T23:57:40.466Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06046560"
    },
    {
      "nct_id": "NCT07325435",
      "title": "Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes (T2DM)"
      ],
      "interventions": [
        {
          "name": "SGLT-2 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "GLP1-RA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MaryAnn Banerji",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "24 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "24 Years to 80 Years"
      },
      "enrollment_count": 60,
      "start_date": "2024-12-21",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-08",
      "last_synced_at": "2026-09-30T23:57:40.466Z",
      "location_count": 1,
      "location_summary": "Brooklyn, New York",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07325435"
    }
  ]
}